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MATERIALS AND METHODS
In vitro tumor cell exfieriments
Female Buffalo rats (R.B.I., Rijswijk, the Netherlands), weighing 150-170 g, were kept in an artificially illuminated room (08.30-20.30 h) with food and water ad libitum. The animals were inoculated subcutaneously between the scapulae with a cell suspension ofthe transplantable, PRL-secreting 7315b rat pituitary tumor as described in detail elsewhere [20] . Three to four weeks after inoculation of the tumor cell suspension a tumor of approximately 20 cm2 has grown on the back of the animals. At this moment the animals were killed by an overdose of ether anesthesia and the tumor was carefully removed and collected in a sterile saline solution (9 g/l NaCl) .
731513 pituitary tumor cells were isolated by mechanical dispersion, The isolated tumor was washed twice with calcium-, magnesium-free Hank's balanced salt solution (HBBS) supplemented with 1% human serum albumin (HSA), penicillin ( lo5 U/l), streptomycin (100 kg/l), fungizone (0.5 mg/l) and sodium bicarbonate (0.4 g/l final concentration).
The capsula of the tumor was carefully removed, after which the tumor was minced into small pieces. The remaining suspension of tumor tissue was gently vortexed for 30 s. After vortexing the suspension was centrifuged at 600 g for 5 min and the pellet was washed twice with HBSS + HSA. The remaining pellet was resuspended in HBSS + HSA and the suspension was filtered over a nylon gauze. In order to separate vital from non-vital cells the suspension was layered on Ficoll-Isopaque (density 1.077 g/ml; prepared by the Dijkzigt Hospital Pharmacy, Rotterdam, the Netherlands) and centrifuged at 500 g for 20 min. The interphase containing vital cells was collected and washed twice with HBSS + HSS. Finally, the cells were resuspended in culture medium. The culture medium used in all experiments consisted of minimal essential medium with Earle's salts (MEM) supplemented with MEM non-essential amino acids, sodium pyruvate ( 1 mmol/l), 10% fetal calf serum, penicillin (10" U/l), streptomycin (100 pg/l), f un izone g (0.5 mg/l), L-glutamine (2 mmol/l) and sodium bicarbonate (2.2 g/l final concentration).
The medium was adjusted to pH 7.4 with 1 mol/l NaOH. The 7315b pituitary tumor cells were seeded at a density of 20,000 cells per well in 1 ml of culture medium in 24- in the culture media were measured by a double antibody RIA using materials and protocols supplied by the distribution officer of the NIADDK. All results are expressed in rat prolactin reference preparation-1 (RP-1).
The DNA content of the tumor cells was determined as described in detail elsewhere [21] . The method is based on a DNA-dependent fluorescence enhancement of a fluorochrome. In short, cultured tumor cells, which did not attach to the floor of the wells, were collected at the end of the incubation period and washed twice with an ice-cold saline solution. The remaining cell pellet was stored at -20°C until analysis. The cells were extracted with 300 ~1 ammonia solution (1 mol/l) + Triton Xl00 (0.2% v/v) by sonification during 5 s at amplitude 15 (Soniprep 150; MSE). Thereafter 2 ml assay buffer ( 100 mmol/l NaCI, 10 mmol/l EDTA, 10 mmol/l Tris; pH 7.0) was added. The remaining solution was centrifuged at 2000 g during 5 min and 100 ~1 aliquots of the supernatant were mixed with 1.5 ml Hoechst dye H33258 (100 ng/ml). Each experiment was done three times, the results shown relate to a single experiment.
All data are expressed as mean * S.E.
In vivo tumor experiments
In two experiments the effect of GH administration on the growth of the 7315b tumor and on reversal (experiment 1) or prevention (experiment 2) of tumor-induced cachexia was evaluated. Tumor growth was evaluated by expressing tumor size in centimeters squared (maximum length X maximum width) which has been shown to be closely correlated with tumor weight [22] . In the first experiment the effects of administration of 1 mg GH/rat/day (Humatrope, Eli Lilly & Co, Indianapolis) subcutaneously in 0.25 ml diluent starting on day 13 after tumor implantation until the end of the experiment (day 23) were evaluated, while in the second experiment the effects of GH administration for 15 days starting on the day ofinoculation were evaluated. In both experiments tumor-bearing controls received daily injections of diluent only while in the second experiment the effects of either GH or diluent was evaluated in non-tumor-bearing controls as well. Each group of animals consisted of six rats.
Plasma IGF-I levels were measured in EDTA plasma obtained from the tail vein during the exper-iment or after decapitation at the end of the experiment. The commercial kit for the determination of IGF-I from the Nichol's Institute of Diagnostics (San Juan Capistrano, CA, U.S.A.) was used. The intra-assay cv was 7.2 and the inter-assay cv 12.8%. PRL was determined in the same samples by double antibody RIA as described above.
Statistical evaluation
Statistical analysis was done by analysis of variance, followed by Duncan's test for determining the differences between control and experimental groups. In the in viuo experiments changes in body weight were evaluated by Student's unpaired t test.
RESULTS
The effects of IGF-I and GH on PRL secretion and DNA content of cultured 73 156 tumor cells
The 73 15b tumor cells were cultured for a period of 6 days. The effects of a wide concentration range of IGF-I (0.5-50 nmol/l) and GH (0.23-45 nmol/l) were investigated ( DNA content in a dose-dependent manner, 10 nmol/l being the maximal stimulatory concentration (stimulation by 1, 5, 10 and 50 nmol/l IGF-I being 24, 37, 50 and 55% respectively, 1 and 5 vs. 0.5 nmol/l: P < 0.05; 10 and 50 vs. 1 nmol/l: P < 0.01). We also measured the IGF-I concentration of the culture medium used in these experiments: the final IGF-I concentration ofthe medium to which the control cells were exposed amounted to 0.2 nmol/l.
Human GH in a concentration between 0.23 and 45 nmol/l did not affect PRL release, while it did also not influence the DNA content of the tumor cells after 6 days of culture (Fig. 1) . In the first experiment GH was injected daily from day 13 till 23 after tumor implantation. GH administration did not affect pituitary tumor growth: tumor size (as expressed in cm2) did not differ from that found in tumor-bearing animals which received the diluent only (Fig. 2) . In contrast, however, the GH-treated tumor bearing rats had gained weight considerably.
In Fig. 2 it is shown that tumor-bearing control animals gained 
t 6 g (mean 2 S.E.M.) in weight during the
10 day placebo treatment period, while the GH treated tumor-bearing rats gained 24.3 + 1 g.
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After deduction of the mean tumor weight (35.1 + 5 g in the placebo treated and 40.5 k B in the GH-treated animals; NS) the weight of the placebo-treated animals amounted to 166 t 6 g, indicating a mean body weight gain of only 3 k 2 g, in comparison with the mean body weight prior to tumor implantation.
The actual mean body weight ofthe GH-treated group at the end ofthe experiment amounted to 180 rt 4g (220.5 t 5.4 minus 40.5 k 2). Therefore the GH-treated animals had gained 18 + 2 g in weight during the 22 day investigational period. This weight gain did not differ from that observed in non-tumor-bearing controls (starting weight 161 + 2.8, final weight 175.3 k 3.7) but was higher than that seen in the tumor-bearing control rats (P < 0.01). In comparison with non-tumor-bearing controls plasma IGF-I levels were slightly lowered on day 12 after tumor implantation (NS , Table la ). This decrease was statistically significant in the tumor-bearing controls 18 and 22 days after tumor implantation (P < 0.05), while GH treatment in tumor-bearing animals resulted in a significant stimulation of IGF-I to levels which were comparable with those observed in non-tumor-bearing controls (both on day 18 and 22: P < 0.05 vs. tumor-bearing controls).
Prolactin levels in the GH treated tumor-bearing group did not differ significantly from the placebotreated tumor-bearing animals (1133 2 156 vs. 771 + 163 ng/ml), though both were significantly higher compared with the non-tumor-bearing controls (81 k 32).
In the second experiment GH administration was started on the day of tumor implantation and continued for 15 days. Again no significant effect of GH administration on tumor growth was observed (Fig. 3) . GH exerted powerful stimulatory effects on body growth both in the non-tumorand in the tumor-bearing animals. The placebo-treated nontumor-bearing rats gained 14 t 2 gin weight, while in the GH-treated control group this amounted to 33 + 3 g (P < 0.01). The tumor-bearing placebotreated rats gained 34 + 4 g in weight, but after deduction of tumor weight (26 2 4 g) net weight gain was only 8 k 2 g. Growth hormone administration to tumor-bearing animals resulted in a total weight gain of 49 2 4 g; after deduction of tumor weight (29 k 7): 20 -+ 2 g (P < 0.01 vs. tumorbearing placebo-treated rats). After 15 days of GH treatment plasma IGF-I levels in the GH treated non-tumor-bearing rats were significantly elevated compared with the placebo-treated non-tumor-bearing animals (P < 0.05; Table 1 b). The consequences of tumor implantation on IGF-I levels again became evident: both on day 16 and 22 they were significantly suppressed in comparison with the placebo-treated non-tumorbearing rats (P < 0.05 in both instances). Administration ofGH to tumor-bearing rats resulted already on day 9 but also on day 16 in a stimulation of IGF-I levels, which were significantly higher than in the placebo-treated tumor-bearing animals (P < 0.05). These levels were, both on day 9 and 16, similar to those observed in GH treated nontumor-bearing rats, and on day 16 also higher than in placebo treated non-tumor-bearing controls (P < 0.05). On day 22 the stimulatory effects of GH administration in the first 15 day period had ceased and IGF-I levels had indeed decreased to levels comparable with those in the placebo-treated tumor-bearing group. PRL levels in the GH-treated tumor-bearing group again did not differ significantly from the placebo-treated tumor-bearing rats (618 + 195 vs 520 4 103 ng/ml). PRL levels were elevated in both tumor-bearing groups compared with both non-tumor-bearing groups (PRL level 35 + 6 in the non-tumor placebo-treated and 26 * 7 ng/ml in the non-tumor GH-treated rats). from investigations into the presence of IGF-I binding sites on the rat pituitary tumor cell line 7315b used in this study indicate indeed the presence of specific high affinity IGF-I binding sites on this tumor.
DISCUSSION
The results of the in vitro studies are in accordance with similar studies in other cancer cell lines, in that it was shown that IGF-I induced cell proliferation and protein (in this case PRL) secretion. GH itself did not induce either effect.
The results of the in vivo studies show that GH administration for 10-15 days prevents tumorinduced cachexia without stimulating tumor growth measured in cm2 or PRL secretion. On a weight basis we used 120-240 times the GH dosage used in human studies to induce an anabolic state [38] .
The discrepancy between the (mitogenic) effect of IGF-I in vitro and the absence ofeffects ofelevated IGF-I levels on tumor growth in vivo might be explained by the possibility with the low IGF-I levels in cachectic animals are sufficient to optimize tumor growth, since the lowest IGF-I level measured in vivo is 14 nM, while levels of 10 and 50 nM in the in vitro experiments stimulated cell proliferation to a similar extent. An auto-or paracrine effect of IGF-I generated by the tumor cells themselves cannot be excluded but seems unlikely since we found virtually no IGF-I production by these cells in vitro IGF-I (concentration in the control culture medium after 6 days 0.2 nM).
Our results are in disagreement with the results of Svaninger et al. [39] , who demonstrated no improvement ofbody composition and muscle wasting (nor an increase in tumor growth) by GH administration in adult, non-growing, sarcomabearing mice, while in hypophysectomized rats GH administration stimulated body and tumor growth to a similar extent. In their sarcoma tumor model in intact animals GH levels were elevated from day 8 after tumor implantation, explained by the authors as a way to promote endogeneous substrate mobilization.
The exogeneous GH dosage was only 100 pg/lOO g body weight day (as opposed to our GH dose of 1 mg/rat, which corresponds to 600 pg/ 100 g body weight/day) which was insufficient to stimulate growth in freely fed control mice. In their study no IGF-I levels were reported.
In our study the decrease of IGF-I levels in tumorbearing rats reflects the tumor induced cachexia [40. 411 and was reversible by GH administration. IGF-I levels decreased to the low level observed in untreated tumor-bearing rats within days after cessation of GH administration.
In conclusion, tumor-induced cachexia in this rat model can be prevented by exogenous GH administration without an increase in tumor mass, even though this tumor model contains specific binding sites for IGF-I and the cultured tumor cells respond to exposure to IGF-I with a mitotic response. 
